Pharvaris announced positive Phase 3 data for deucrictibant IR, showing rapid symptom relief and resolution for HAE attacks, published in The Lancet. This news is a significant positive for the company as it supports the ongoing NDA and MAA reviews, potentially leading to market approval.
Pharvaris reported that its Phase 3 RAPIDe-3 trial results for deucrictibant IR, an on-demand treatment for HAE attacks, were published in The Lancet. The data indicates rapid symptom relief (1.28 hours) and complete resolution (11.95 hours) with a well-tolerated safety profile. This is a crucial development as it provides strong clinical validation for the drug, bolstering the company's ongoing New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions to regulatory authorities. For traders, this news presents a short-term opportunity for PHVS due to increased confidence in regulatory approval and long-term potential if the drug successfully enters the market, addressing a significant unmet medical need for HAE patients. The key risk is still regulatory approval, but the Lancet publication significantly de-risks this process.